UNSPSC 51143300: Combination anticonvulsants

This classification denotes combination drugs used to prevent seizures or reduce their severity. Typical combination anticonvulsant constituients are phenobarbital and phenytoin.

UNSPSC 51143300 Combination anticonvulsants is a Class code, but the recent state and local opportunities tagged under it reflect a broader pharmaceutical procurement pattern: Seminole County, Florida is procuring naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and over-the-counter products through an RFP. State and local buying under this code spans public health departments, state health agencies, and cooperative purchasing vehicles seeking pharmaceutical products for community health initiatives, emergency response, and broad population coverage. Issuing bodies range from county-level health authorities to state-level health and human services commissions, with cooperative purchasing alliances like MMCAP serving multiple jurisdictions across participating states. The scope of work encompasses product procurement with specific compliance and delivery requirements, including FDA certification, Good Manufacturing Practices (cGMP) compliance, and Drug Supply Chain Security Act (DSCSA) adherence when applicable.

Recent activity concentrates in Texas, Florida, and Minnesota-led multistate programs. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas HHS RFI (HHS0017013), posted April 3, 2026, explored vendor capabilities for direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; and the MMCAP RFP (S1070000015802), posted January 20, 2026, requested generic multi-source pharmaceuticals and OTC products from manufacturers, with proposals due March 26, 2026, and contract effectiveness planned for July 1, 2026. The MMCAP solicitation specifies pricing evaluation weighted at 75 percent, administrative compliance at 15 percent combined, and EDI capability and administrative-fee agreement at 10 percent combined, with winners subject to $200 to $1,500 per-violation performance penalties. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and comply with E-Verify and drug-free workplace requirements where applicable.